Overview

Apremilast 30mg*60 tablets, sold as Apores by Tlph, are an oral small-molecule immunomodulator for psoriasis and psoriatic arthritis. Distinct from biologic injections, apremilast works through an intracellular enzyme rather than blocking an external cytokine. This article explains the PDE4 mechanism and why the 30mg twice-daily presentation fits long-term oral management.

How It Works

Apremilast is a phosphodiesterase-4 inhibitor. By blocking PDE4, it reduces breakdown of cyclic AMP inside immune and epithelial cells, raising intracellular cAMP. Higher cAMP dampens the activity of pro-inflammatory transcription factors and lowers the release of tumour necrosis factor, interleukin-23, and interleukin-17, the same axes driving psoriatic disease. The mechanism is oral, intracellular, and non-immunosuppressive in the conventional sense, which shapes its safety and combination profile versus biologics.

Indications

Apremilast is indicated for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy and for active psoriatic arthritis. The 30mg strength is the maintenance dose after a brief titration, supporting both skin and joint manifestations in a single tablet.

Dosage & Administration

Treatment starts low and titrates up over the first week to minimise gastrointestinal upset, then continues at 30mg twice daily. The 60-tablet bottle covers one month of maintenance. Tablets are taken with or without food; dose adjustments are generally not needed for mild renal impairment, though severe impairment requires caution. Patients should be advised about the transient initial nausea.

Storage & Sourcing

Store at room temperature, away from moisture and direct heat, in the closed bottle. Tlph's Apores supplies a generic oral alternative to branded apremilast, supporting cost-sensitive tenders. Buyers should verify the marketing authorisation, GMP certificate, and batch traceability, and confirm labelling matches the destination market's prescribing information.

Apremilast's oral, non-injectable profile fits patients who decline or cannot access biologics, and the 30mg twice-daily tablet supports long-term use without infusion capacity. B2B buyers should pair it with patient-education material on the first-week nausea, since managed expectations improve persistence and reduce wasted starter packs. Unlike biologics, apremilast needs no baseline tuberculosis screening for immunosuppression, which simplifies onboarding, but renal-impaired patients still need dose caution, so labelling and pharmacist briefing should reflect that nuance.

FAQ

Q: How does PDE4 inhibition differ from a biologic?

A: Apremilast acts inside the cell on cyclic AMP breakdown rather than neutralising an external cytokine, so it is an oral, non-injectable option.

Q: Why titrate apremilast at the start?

A: A short low-dose ramp reduces the transient nausea and diarrhoea seen most often in the first week.

Q: Is the 30mg dose used from day one?

A: No. Patients titrate up over approximately one week before settling on 30mg twice daily as maintenance.